Table 1.
Demographics and Clinical characteristics of 173 patients with Behcet’s disease
| Characteristics | BD (n = 173) | ATB (n = 18) | LTB (n = 29) | Previous TB (n = 12) | Non-TB (n = 114) |
|---|---|---|---|---|---|
| Age (years, mean ± SD) | 37.07 ± 14.74 | 36.78 ± 10.61 | 43.52 ± 15.23 | 42.75 ± 14.06 | 34.87 ± 14.76 |
| Male (percentage) | 114 (65.9%) | 11 (61.1%) | 23 (79.3%) | 5 (41.7%) | 75 (65.8%) |
| BDCAF score (median, range) | 2 (0–5) | 1.5 (1–5) | 2 (0–5) | 3 (0–5) | 2 (0–5) |
| Clinical features of BD | |||||
| Oral ulcer | 170 (98.3%) | 18 (100%) | 28 (96.6%) | 12 (100%) | 112 (98.2%) |
| Genital ulcer | 101 (58.4%) | 15 (83.3%) | 20 (68.9%) | 9 (75%) | 57 (50%) |
| Skin lesions | 101 (58.4%) | 13 (72.2%) a | 10 (34.5%) | 10 (83.3%) | 68 (59.6%) |
| Erythema nodosa | 53 (30.6%) | 9 (50%) a | 6 (20.6%) | 5 (41.6%) | 33 (28.9%) |
| Pathergy reaction | 39 (22.5%) | 7 (38.9%) | 7 (24.1%) | 3 (25%) | 22 (19.3%) |
| Gastrointestinal involvement | 68 (39.3%) | 5 (27.7%) | 12 (41.4%) | 5 (41.7%) | 46 (40.3%) |
| Vascular involvement | 49 (28.3%) | 7 (38.9%) | 9 (31%) | 3 (25%) | 30 (26.3%) |
| Ocular involvement | 33 (19%) | 4 (22.2%) | 3 (10.3%) | 1 (8.3%) | 25 (21.9%) |
| Neurologic involvement | 26 (15%) | 1 (5.5%) | 3 (10.3%) | 3 (25%) | 19 (16.7%) |
| Treatment | |||||
| Glucocorticoid | 113 (65.3%) | 12 (66.7%) | 22 (75.9%) | 6 (50%) | 73 (64%) |
| Immunosuppressive agents | 94 (54.3%) | 7 (38.9%) | 16 (55.2%) | 8 (66.7%) | 63 (55.3%) |
| Biological agents | |||||
| Infliximab/Etanercept | 12 (6.9%) | 2 (11.1%) | 2 (6.9%) | 1 (8.3%) | 7 (6.1%) |
ATB compare with LTB; ap<0.05
BD Behçet’s disease, TB tuberculosis, ATB active tuberculosis, LTB latent tuberculosis